SINGAPORE, June 13, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.
Tessa’s scientific session will focus on CD30 CAR-T targeting of CD30+ lymphomas and will feature a presentation from Dr. Ivan Horak, Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics. The discussion will be moderated by Dr. Han Chong Toh, Deputy Medical Director, National Cancer Centre Singapore (NCCS), Associate Professor, Cancer & Stem Cell Biology Program and SingHealth-Duke Global Health Institute, Duke-NUS, and Head of Cancer Immunotherapy at the SingHealth Duke-NUS Cell Therapy Centre.
Tessa is currently advancing two clinical programs leveraging distinct CD30 CAR-T technologies for the treatment of CD30+ lymphomas. Tessa’s lead clinical program – TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma. Additionally, Tessa is developing an allogenic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomas. Data demonstrating the safety and efficacy of both programs was previously presented at the 2021 ASH Annual Meeting.
“We are very pleased to host a scientific session at the SDCT-REMEDIS Cell Therapy Conference 2022 as it provides an opportunity to educate researchers on opportunities to treat CD30-positive lymphomas via CAR-T and the unique approaches being advanced by Tessa,” said Dr. Horak. “We look forward to progressing clinical programs investigating our autologous (TT11) and allogenic (TT11X) CAR-T technologies during 2022, with several development milestones expected throughout the year.”
Details on the scientific session are as follows:
| Presentation Title: | CD30 CAR-T targeting of CD30+ Lymphomas |
| Moderator: | Dr. Han Chong Toh, Deputy Medical Director, National Cancer Centre Singapore (NCCS), Associate Professor, Cancer & Stem Cell Biology Program and SingHealth-Duke Global Health Institute, Duke-NUS, and Head of Cancer Immunotherapy at the SingHealth Duke-NUS Cell Therapy Centre |
| Presenter: | Dr. Ivan Horak, Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics |
| Date and Time: | June 23, 2022, 3:25 p.m. (SGT)/3:25 a.m. (EDT) |
About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30-CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (Phase 2). TT11 has been granted RMAT designation by the FDA and PRIME designation by European Medicine Agency. Tessa is also advancing an allogeneic “off-the shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphomas. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. For more information on Tessa, visit www.tessacell.com.
Cautionary Note on Forward Looking Statements
This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate,” “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body.
Tessa Therapeutics Investor Contact
Wilson W. Cheung
Chief Financial Officer
wcheung@tessacell.com
Tessa Therapeutics Media Contact
Tiberend Strategic Advisors, Inc.
Bill Borden
+1-732-910-1620
bborden@tiberend.com
Dave Schemelia
+1-609-468-9325
dschemelia@tiberend.com
